TrialNature communications2024

Clinical and biomarker results from a phase II trial of combined cabozantinib and durvalumab in patients with chemotherapy-refractory colorectal cancer (CRC): CAMILLA CRC cohort.

Anwaar Saeed et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.